跳至主要内容
临床试验/ACTRN12622000036718
ACTRN12622000036718尚未招募未知

Physical activity and health: the effect of GoldFit YMCA participation on central and peripheral chemoreflexes and cerebrovascular reactivity in older adult humans

niversity of Auckland0 个研究点目标入组 50 人开始时间: 2022年1月17日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
60 Years 至 o limit(—)
性别
All

入选标准

  • Aged >60 years old
  • - Men and women
  • - Free of chronic cardiovascular, respiratory, metabolic, or neurological disease
  • - Not currently engaging in regular exercise and have not been in a regular exercise routine for >12 months, and who are newly enrolled or intending to enroll to begin exercise training in the YMCA GoldFit exercise training programme, aged >60 years old

排除标准

  • BMI <18 kg/m2
  • Current smoker
  • Current users of recreational drugs
  • Current abusers of alcohol
  • Recent (<12 month) history of hospital admission
  • Significant arrhythmias (e.g., atrial fibrillation, previous VT / significant ventricular ectopy)
  • Hemodynamically significant valvular heart disease (e.g., stenosis, mechanical valve replacement)
  • Severe left ventricular systolic dysfunction
  • Recent acute coronary syndrome (<12 months) (e.g., MI, angioplasty, unstable angina)
  • Previous coronary artery bypass surgery
  • Secondary causes of hypertension (e.g., phaeochromocytoma)
  • Recent stroke/TIA (<12 months)
  • Inability to fully or appropriately provide consent (e.g., language issue, reading capability)
  • Underlying medical conditions, which in the opinion of the Investigator place the participant at unacceptably high risk for participating in the study.
  • Chronic and systemic illness including:
  • Severe respiratory disease (e.g., chronic obstructive pulmonary disease);
  • Severe, uncontrolled type II diabetes;
  • Current treatment for cancer or complete remission <5 years
  • Connective tissue or inflammatory disease
  • Neurological / psychiatric disease (e.g., peripheral neuropathy, dementia, Parkinson’s, epilepsy)
  • Infection or pyrexial illness
  • Uncontrolled thyroid disorders
  • Renal impairment (e.g., eGFR <60)
  • Liver disease

研究者

发起方
niversity of Auckland

相似试验